Cure My Disease

Don't miss your cure!

 Log in / Sign up

Same position, sharper picture: new method aims to line up breast scans

NCT ID NCT07883460

Diagnosis Sponsor: Universität Münster Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

PET/CT and MRI scans of the breast are usually taken with the patient in different body positions, which can shift the breast's shape and make it hard to compare findings. This study tests whether scanning women with breast cancer in a dedicated prone breast position during PET/CT can reduce those differences. Participants, who are already scheduled for PET/CT and PET/MRI as part of their care, receive an extra low-dose CT and an additional PET acquisition using the tracer already given. Researchers then develop and evaluate image registration methods to align the scans and measure how accurately findings transfer between them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prone breast PET/CT imaging with a dedicated positioning setup
What this could lead to
If it works, doctors could match PET/CT and MRI findings more precisely, which may improve how breast cancer is assessed and tracked.
What could go wrong
This is a small imaging study with 20 participants, so the method may not work as well in routine practice. The extra scans add a few minutes of lying still and a small amount of radiation from the low-dose CT.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex * Clinically indicated PET/CT and PET/MRI of the breast * Histologically confirmed breast cancer Exclusion Criteria: * Age under 18 years * Pregnancy * Lack of capacity to provide informed consent * Possible conception within the previous 14 days * Inability to remain still in the prone position for approximately 10 minutes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast - female are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast - female Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Nuclear Medicine, University Hospital Münster

    Münster, North Rhine-Westphalia, 48149, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.